New hope for psoriasis patients who Didn't respond to leading biologics
NCT ID NCT06336343
First seen Nov 20, 2025 · Last updated Apr 25, 2026 · Updated 21 times
Summary
This study looked at whether bimekizumab can safely and effectively treat moderate-to-severe plaque psoriasis in adults who did not get better with similar drugs (IL-17 or IL-23 blockers). Bimekizumab works by reducing inflammation in the body. The study involved 60 participants and measured how much psoriasis cleared up after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Windsor Dermatology - Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, 08520, United States
Conditions
Explore the condition pages connected to this study.